ALEC · Alector, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.05M | - | $15.34M | $15.08M | $15.90M | - | $15.34M | $15.08M | $15.89M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $17.86M | - | $29.35M | $27.61M | $33.64M | - | $48.00M | $46.31M | $45.17M | - |
| SG&A | $8.11M | - | $11.52M | $14.40M | $14.73M | - | $15.78M | $14.38M | $14.43M | - |
| Total Operating Expenses | $25.96M | - | $40.87M | $42.01M | $48.37M | - | $63.78M | $60.69M | $59.60M | - |
| D&A | $1.08M | - | - | - | $984.0K | - | - | - | $1.44M | - |
| Operating Income | ($24.92M) | - | ($37.61M) | ($34.14M) | ($44.70M) | - | ($48.43M) | ($45.61M) | ($43.71M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $73.0K | $7.0K | - |
| Net Income | ($22.93M) | - | ($34.67M) | ($30.52M) | ($40.47M) | - | ($42.22M) | ($38.68M) | ($36.08M) | - |
| EPS - Basic | ($0.21) | - | ($0.34) | ($0.30) | ($0.41) | - | ($0.43) | ($0.40) | ($0.38) | - |
| EPS - Diluted | ($0.21) | - | ($0.34) | ($0.30) | ($0.41) | - | ($0.43) | ($0.40) | ($0.38) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $76.96M | $65.80M | $76.50M | $44.77M | $37.97M | $33.02M | $37.16M | $47.55M | $72.55M | $74.56M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.42M | $1.69M | $4.76M | $2.22M | $2.33M | $2.21M | $5.02M | $4.38M | $4.59M | $3.77M |
| Current Assets | $215.08M | $266.45M | $300.38M | $319.18M | $366.65M | $424.82M | $469.36M | $519.70M | $581.39M | $565.81M |
| Total Assets | $239.92M | $293.24M | $335.29M | $356.42M | $408.30M | $468.30M | $516.02M | $570.73M | $635.49M | $621.83M |
| Current Liabilities | $40.97M | $69.50M | $79.96M | $84.35M | $109.77M | $125.06M | $142.53M | $147.68M | $164.92M | $177.95M |
| Long-term Debt | $8.29M | $9.32M | $9.61M | $9.54M | $9.46M | $9.39M | - | - | - | $0 |
| Total Liabilities | $229.53M | $262.59M | $277.57M | $285.25M | $313.69M | $341.50M | $397.09M | $420.16M | $456.59M | $487.67M |
| Stockholders' Equity | $10.38M | $30.65M | $57.71M | $71.17M | $94.61M | $126.80M | $118.93M | $150.57M | $178.91M | $134.16M |
| Retained Earnings | ($994.99M) | ($972.06M) | ($934.79M) | ($900.12M) | ($869.60M) | ($829.13M) | ($827.05M) | ($784.83M) | ($746.16M) | ($710.08M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($49.81M) | - | - | - | ($60.78M) | - | - | - | ($61.35M) | - |
| Investing Cash Flow | $60.95M | - | - | - | $65.73M | - | - | - | ($11.77M) | - |
| Financing Cash Flow | $25.0K | - | - | - | $0 | - | - | - | $71.11M | - |
| CapEx | $118.0K | - | - | - | $20.0K | - | - | - | $533.0K | - |
| Free Cash Flow | ($49.93M) | - | - | - | ($60.80M) | - | - | - | ($61.88M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -2382.3% | - | -245.1% | -226.3% | -281.1% | - | -315.7% | -302.4% | -275.0% | - |
| EBITDA margin | -2279.0% | - | - | - | -274.9% | - | - | - | -265.9% | - |
| Net margin | -2192.2% | - | -226.0% | -202.4% | -254.5% | - | -275.2% | -256.4% | -227.0% | - |
| Free cash flow margin | -4773.5% | - | - | - | -382.4% | - | - | - | -389.3% | - |
| FCF / Net income | 2.18 | - | - | - | 1.50 | - | - | - | 1.72 | - |
| R&D / Revenue | 1707.2% | - | 191.3% | 183.1% | 211.6% | - | 312.9% | 307.1% | 284.2% | - |
| SG&A / Revenue | 775.1% | - | 75.1% | 95.5% | 92.6% | - | 102.8% | 95.3% | 90.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.6% | - | -10.3% | -8.6% | -9.9% | - | -8.2% | -6.8% | -5.7% | - |
| Return on equity | -220.9% | - | -60.1% | -42.9% | -42.8% | - | -35.5% | -25.7% | -20.2% | - |
| Return on invested capital | -105.4% | - | -44.1% | -33.4% | -33.9% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.25 | 3.83 | 3.76 | 3.78 | 3.34 | 3.40 | 3.29 | 3.52 | 3.53 | 3.18 |
| Quick ratio | 5.25 | 3.83 | 3.76 | 3.78 | 3.34 | 3.40 | 3.29 | 3.52 | 3.53 | 3.18 |
| Cash ratio | 1.88 | 0.95 | 0.96 | 0.53 | 0.35 | 0.26 | 0.26 | 0.32 | 0.44 | 0.42 |
| Leverage | ||||||||||
| Debt / Equity | 0.80 | 0.30 | 0.17 | 0.13 | 0.10 | 0.07 | - | - | - | 0.00 |
| Debt / Assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 23.11 | 9.57 | 5.81 | 5.01 | 4.32 | 3.69 | 4.34 | 3.79 | 3.55 | 4.64 |
| Liabilities / Assets | 0.96 | 0.90 | 0.83 | 0.80 | 0.77 | 0.73 | 0.77 | 0.74 | 0.72 | 0.78 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.05 | 0.04 | 0.04 | - | 0.03 | 0.03 | 0.03 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 22.9x | - | 5.3x | 2.0x | 1.3x | - | 3.8x | 2.9x | 3.2x | - |
| P / S | 227.3x | - | 19.8x | 9.3x | 7.7x | - | 29.6x | 29.1x | 35.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -93.4% | - | 0.0% | 0.0% | 0.0% | - | 68.4% | -73.2% | -4.0% | - |
| Revenue CAGR (3y) | -60.2% | - | 1.1% | -42.6% | -13.4% | - | -56.2% | 31.9% | 57.0% | - |
| Revenue CAGR (5y) | -23.9% | - | 21.0% | 36.6% | 17.3% | - | 18.7% | 16.2% | 23.2% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 44.2% | - | 22.4% | 25.1% | -2.3% | - | 4.2% | -1170.7% | 12.8% | - |
| Net income growth (YoY) | 43.3% | - | 17.9% | 21.1% | -12.2% | - | 5.1% | - | 21.3% | - |
| EPS growth (YoY) | 48.8% | - | 20.9% | 25.0% | -7.9% | - | 18.9% | - | 30.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 17.9% | - | - | - | 1.7% | - | - | - | -24.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -89.0% | -75.8% | -51.5% | -52.7% | -47.1% | -5.5% | -26.8% | -23.3% | -2.2% | -37.4% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Alector against the 5 most active filers in the same SIC group.